LINCOLN
Lincoln Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Lincoln Pharmaceuticals Limited (LINCOLN) Stock Analysis & Case Study
Is LINCOLN a good buy? The data-driven verdict.
Lincoln Pharmaceuticals Limited (LINCOLN) trades at ₹600,on the numbers it worth a closer look, a Downstox Snapshot Score of 65/100.
On the numbers, Lincoln Pharmaceuticals Limited (LINCOLN) worth a closer look, a Downstox Snapshot Score of 65/100, weighing inexpensive at 13.7× earnings, ROE of 12.3%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
LINCOLN fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How LINCOLN ranks against the 2,373 companies in our screener
- LINCOLN's market cap of 1,202 Cr ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's book value of ₹378 ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's promoter holding of 49.8% ranks in the 29th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's 3-year profit (PAT) growth of 7.0% ranks in the 38th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's 3-year revenue growth of 10.0% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's debt-to-equity ratio of 0.01x is lower than 98% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is LINCOLN overvalued? LINCOLN P/E vs peers
LINCOLN trades at 13.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
LINCOLN share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of LINCOLN history (11%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| LINCOLN 2027 | ₹345 | ₹616 | ₹1,099 | +3% |
| LINCOLN 2028 | ₹283 | ₹632 | ₹1,410 | +5% |
| LINCOLN 2029 | ₹245 | ₹649 | ₹1,718 | +8% |
| LINCOLN 2030 | ₹215 | ₹666 | ₹2,059 | +11% |
| LINCOLN 2031 | ₹198 | ₹683 | ₹2,354 | +14% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability LINCOLN goes up, or doubles?
The bull case for LINCOLN
- LINCOLN's P/E of 13.7x is lower than 78% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- LINCOLN's return on equity of 12.3% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,718.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹245.
LINCOLN volatility & expected range, how bumpy is the ride?
Over the last 9.8 years LINCOLN compounded at 11%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹345-₹1,099, the honest backbone behind any single price target.
LINCOLN price forecast, the full 60-month probability fan
LINCOLN price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds LINCOLN hits common targets within the simulated horizon?
Full multi-horizon detail on the LINCOLN price target & forecast page.
LINCOLN Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. LINCOLN scores 6/8, mixed financial health.
LINCOLN MTF margin & leverage across 8 brokers
Margin Trading Facility lets you buy LINCOLN with part of the capital. Lower margin % = higher leverage. Rates compared across 8 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 35.18% | 2.8× |
| Groww | 60.00% | 1.7× |
| Dhan | 50.00% | 2.0× |
| Kotak Neo | 100.00% | 1.0× |
| Pocketful | 35.77% | 2.8× |
| Anand RathiCHEAPEST | 35.18% | 2.8× |
| Bajaj Broking | 50.00% | 2.0× |
| Share India | 35.28% | 2.8× |
Compare every broker on the LINCOLN MTF page.
About Lincoln Pharmaceuticals Limited: sector, index & market-cap context
Lincoln Pharmaceuticals Limited (LINCOLN) is a small-cap NSE-listed company, with a market capitalisation of ₹1,202 Cr. See more stocks on our screener.
How the LINCOLN Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Lincoln Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
LINCOLN analysis, FAQs
Is Lincoln Pharmaceuticals Limited (LINCOLN) a good buy?
On the numbers, Lincoln Pharmaceuticals Limited (LINCOLN) worth a closer look, a Downstox Snapshot Score of 65/100, weighing inexpensive at 13.7× earnings, ROE of 12.3%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is LINCOLN overvalued or undervalued?
LINCOLN trades at 13.7× earnings, inexpensive versus the ~22× long-run Nifty average.
What is the LINCOLN share price target for 2031?
LINCOLN's probability-weighted 2031 median target is ₹683, with an 80% range of ₹198-₹2,354 (10,000-path Monte-Carlo).
What is the probability LINCOLN doubles in 5 years?
The modelled probability of LINCOLN reaching ₹1,200 (2×) within 5 years is 28%.
What is the bull case for LINCOLN?
LINCOLN's P/E of 13.7x is lower than 78% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. LINCOLN's return on equity of 12.3% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in LINCOLN?
No model or past record guarantees future returns, treat this as one input, not a decision.